12,372 trials
Type 2 Diabetes Mellitus
Primary: Change From Baseline in HbA1c at Week 60 — -0.70; -0.66 percentage of glycated hemoglin
Gastroparesis
Primary: GCSI-DD Total Composite Symptom Scores. — 1.89; 1.57; 1.34 score on a scale — p=<0.01
Type 2 Diabetes
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 to Lantus®) — -1.27; -1.23 Percentage of HbA1c — p=0.545
Primary Hyperparathyroidism · Parathyroid Adenoma · Parathyroid Hyperplasia
Primary: Change in Lumbar Spine Bone Mineral Density — 0.030; 0.042; -0.016 g/cm^2 — p=< 0.00001
Heart Transplant Recipients
Primary: Peak Oxygen Consumption — 23.9; 22.0 ml/kg/min
Acquired Immune Deficiency Syndrome (AIDS) · HIV Infections
Primary: Pharmacokinetic (PK) Parameter: AUCtau of Elvitegravir (EVG) (Cohort 1) — 23840.1 hr*ng/mL
Surgery
Primary: Percent Responder Rates (%) of Bacterial Reduction on the Abdomen and Groin — 93; 86; 50; 25 Percent of Sites
Age-Related Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) — 6.26; 7.08 letters
Dry Eye Disease
Primary: Change From Baseline in Total Corneal Fluorescein Staining at Day 29 — -2.9; -2.2 score on a scale
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP) — 114.7; -11.2 millimeters of mercury (mmHg)
Social Anxiety Disorder · Performance Anxiety
Primary: VAS-anxiety Immediately After the Impromptu Speech Task — 54.3; 62.6 millimeters (units on a scale) — p=0.056
Urothelial Carcinoma Associated 1 RNA, Human
Primary: Pembro Combo vs Chemo: Progression-free Survival (PFS) Using Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review…
Advanced Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) in Women and Men With Hormone Receptor Positiv, HER-2 Negative Breast Cancer Treated With Ribocilib and Letrozole — 63.2; 57.7; 56.5; 60.8…
Hypoglycemia · Diabetes Mellitus, Type 1
Primary: Time to Plasma Glucose Recovery. — 10.0; 35.0 minutes — p=<0.0001
PostTraumatic Stress Disorder
Primary: Level of Interleukin-6 (IL6) — 0.88; 0.84; 1.77; 2.11 pg/ml